101094-05-7

Basic information

• Product Name: Modafinil Carboxylate Sulfone
• Synonyms: 2-[(Diphenylmethyl)sulfonyl]acetic Acid;Modafinil Carboxylate Sulfone;NSC 114215;ArModafinil IMpurity D
• CAS NO: 101094-05-7
• Molecular Formula: C₁₅H₁₄O₄S
• Molecular Weight: 290.33
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 101094-05-7.mol

Chemical Properties

• Melting Point: 141-142 °C(Solv: benzene (71-43-2))
• Boiling Point: 552.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.330±0.06 g/cm3(Predicted)
• PKA: 2.41±0.10(Predicted)
• CAS DataBase Reference: Modafinil Carboxylate Sulfone(CAS DataBase Reference)
• NIST Chemistry Reference: Modafinil Carboxylate Sulfone(101094-05-7)
• EPA Substance Registry System: Modafinil Carboxylate Sulfone(101094-05-7)

Safety Data

• Hazardous Substances Data: 101094-05-7(Hazardous Substances Data)

Usage

Uses

Modafinil derivative as PAF antagonist

Upstream product

• 63547-22-8 (benzhydrylthio)acetic acid 
• 91-01-0 1,1-Diphenylmethanol 

Downstream Products

• 16003-62-6 Diphenylmethyl-dibrommethyl-sulfon 
• 16003-65-9 Diphenylmethyl-dichlormethyl-sulfon 

Relevant articles and documents

Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid

A process for the oxidation of thioethers to sulfoxides or sulfones or for the oxidation of sulfoxides to sulfones by treatment of thioethers or sulfoxides with an oxidizing amount of ε-phthalimidoperhexanoic acid is particularly useful for the preparation of compounds of industrial interest, in particular pharmaceuticals for human or veterinary use.

Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group

A process for the oxidation of thioethers to sulfoxides or sulfones or for the oxidation of sulfoxides to sulfones by treatment of thioethers or sulfoxides with an oxidizing amount of ε-phthalimidoperhexanoic acid is particularly useful for the preparation of compounds of industrial interest, in particular pharmaceuticals for human or veterinary use.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.

Synthesis and Structure-Activity Relationships of 1-Acyl-4-(2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists

A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines, with increased oral activity was prepared and evaluated in vitro in PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP).Oral activity was ascertained through a PAF-induced mortality test in mice (MOR).Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test.Three different types of acylsubstituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups.The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 μM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR-12519, PAG IC50 = 0.041 μM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086.Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests.On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.